Trial Profile
A Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Explore the Safety, Pharmacokinetics and Pharmacodynamics of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Apr 2022 Data from three studies (phase 2 (NCT01498185) and two phase 3 (DEPICT-1, NCT02268214; DEPICT-2, NCT02460978) studies) were used to characterize the dapagliflozin pharmacokinetics (PK) in patients with T1DM published in the Journal of Clinical Pharmacology
- 26 Jun 2018 Results from 2 studies NCT01498185 and NCT02582814 presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 09 Jun 2015 Results of a post hoc analysis of insulin dose adjustment in response to dapagliflozin therapy presented at the 75th Annual Scientific Sessions of the American Diabetes Association.